Table 4.
Odds ratios (ORs) and 95% confidence intervals (CIs) for biliary tract cancers in relation to selected variants in inflammation genes
Gallbladder Cancer | Extrahepatic Bile Duct Cancer | ampulla of Vater Cancer | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene/SNP (dbSNP ID) | Cases | Controls | ORa | 95% CI |
P- trend |
Cases | Controls | OR | 95% CI | P-trend | Cases | Controls | ORa | 95% CI |
P- trend |
Total | 237 | 737 | - | - | - | 127 | 786 | - | - | - | 47 | 786 | - | - | - |
IL10 | |||||||||||||||
Ex5+210C>T (rs3024496) | |||||||||||||||
TT | 223 | 678 | 1.00 | - | 116 | 720 | 1.00 | - | 40 | 720 | 1.00 | - | |||
TC | 12 | 51 | 0.74 | 0.38–1.41 | 9 | 57 | 0.95 | 0.45–1.98 | 7 | 57 | 2.12 | 0.90–5.00 | |||
CC | 0 | 1 | - | - | 0 | 1 | - | - | 0 | 1 | - | - | |||
0.30 | 0.84 | 0.10 | |||||||||||||
TC or CC | 12 | 52 | 0.72 | 0.38–1.38 | 9 | 58 | 0.94 | 0.45–1.96 | 7 | 58 | 2.10 | 0.89–4.96 | |||
IVS1-286G>T (rs3024491) |
|||||||||||||||
GG | 225 | 683 | 1.00 | - | 118 | 726 | 1.00 | - | 40 | 726 | 1.00 | - | |||
GT | 11 | 50 | 0.69 | 0.35–1.35 | 9 | 56 | 0.95 | 0.46–2.00 | 7 | 56 | 2.16 | 0.92–5.11 | |||
TT | 0 | 1 | - | - | 0 | 1 | - | - | 0 | 1 | - | - | |||
0.23 | 0.85 | 0.09 | |||||||||||||
GT or TT | 11 | 51 | 0.67 | 0.34–1.32 | 9 | 57 | 0.94 | 0.45–1.98 | 7 | 57 | 2.14 | 0.91–5.06 | |||
−6653A>C (rs1800872) | |||||||||||||||
AA | 121 | 318 | 1.00 | - | 57 | 340 | 1.00 | - | 19 | 340 | 1.00 | - | |||
AC | 91 | 334 | 0.70 | 0.51–0.96 | 16 | 90 | 0.93 | 0.62–1.41 | 21 | 90 | 1.13 | 0.60–2.15 | |||
CC | 23 | 82 | 0.76 | 0.45–1.26 | 52 | 352 | 1.09 | 0.59–2.01 | 6 | 352 | 1.26 | 0.49–3.26 | |||
0.06 | 0.94 | 0.60 | |||||||||||||
AC or CC | 114 | 416 | 0.71 | 0.53–0.96 | 68 | 442 | 0.97 | 0.66–1.42 | 27 | 442 | 1.16 | 0.63–2.13 | |||
−7334T>C (rs1800871) | |||||||||||||||
TT | 122 | 311 | 1.00 | - | 55 | 334 | 1.00 | - | 20 | 334 | 1.00 | - | |||
TC | 92 | 335 | 0.69 | 0.50–0.94 | 52 | 353 | 0.94 | 0.62–1.42 | 6 | 353 | 1.06 | 0.56–2.00 | |||
CC | 23 | 82 | 0.74 | 0.44–1.23 | 17 | 90 | 1.19 | 0.65–2.16 | 21 | 90 | 1.19 | 0.46–3.07 | |||
0.04 | 0.76 | 0.73 | |||||||||||||
TC or CC | 115 | 417 | 0.70 | 0.52–0.94 | 69 | 443 | 0.99 | 0.67–1.46 | 27 | 443 | 1.09 | 0.60–1.98 | |||
−1116A>G (rs1800896) | |||||||||||||||
AA | 231 | 624 | 1.00 | - | 107 | 664 | 1.00 | - | 38 | 664 | 1.00 | - | |||
AG | 23 | 99 | 0.65 | 0.40–1.06 | 18 | 108 | 1.11 | 0.65–1.93 | 9 | 108 | 1.50 | 0.70–3.21 | |||
GG | 1 | 7 | - | - | 0 | 7 | - | - | 0 | 7 | - | - | |||
0.06 | 0.91 | 0.51 | |||||||||||||
AG or GG | 24 | 106 | 0.63 | 0.40–1.03 | 18 | 115 | 1.04 | 0.60–1.80 | 9 | 115 | 1.41 | 0.66–3.00 | |||
Global p value | 0.10 | 0.94 | 0.25 | ||||||||||||
VEGF | |||||||||||||||
236bp 3’ of STP (rs3025039) |
|||||||||||||||
CC | 172 | 487 | 1.00 | - | 87 | 518 | 1.00 | - | 32 | 518 | 1.00 | ||||
CT | 58 | 21 | 0.72 | 0.51–1.01 | 34 | 236 | 0.87 | 0.56–1.34 | 15 | 236 | 1.03 | 0.55–1.94 | |||
TT | 4 | 22 | - | - | 5 | 25 | 1.20 | 0.44–3.28 | 0 | 25 | - | ||||
0.03 | 0.78 | 0.55 | |||||||||||||
CT or TT | 62 | 43 | 0.70 | 0.50–0.97 | 39 | 261 | 0.90 | 0.60–1.36 | 15 | 261 | 0.93 | 0.49–1.75 |
Adjusted for age and gender.
P value for global test to assess the overall gene effect.